Leveraging models, experimental therapeutics and innovative technologies to improve outcomes of patients with T-cell lymphomas.
The Jain T-cell lymphoma research program strives to advance outcomes of patients with T-cell lymphomas. We seek to develop novel mouse models and cell lines to define molecular alterations that drive and contribute to T-cell lymphomagenesis. We integrate single cell omics, experimental compounds, cellular techniques and genetic screens to identify novel targets for translation to early phase clinical trial.
We are particularly interested in the following:
Determining the role of minimal residual disease in patients with T-cell lymphomas.
Understanding the role of the tumor microenvironment in regulating differential responses to therapies.
Harnessing the ability of myeloid cells to improve anti-tumor responses.